



Mr. MHD SALEEM KHALED

PID NO: 43120

Age: 25 Years Sex: Male DOB: 07-Jul-2000

Reference: Dr. AISHA

Referred Client:

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5070106064

Collected on:

16-Jul-2025 03:25 PM

Registered on:

16-Jul-2025 11:14 PM

Reported on :

16-Jul-2025 11:47 PM

<u>Investigation</u>	Observed Value Flag	<u>Unit</u>	Biological Reference Int	torval as a l
_	Observed value Flag	OIIIL	biological Reference IIII	<u>Method</u>
COMPLETE BLOOD COUNT (CBC)				
HEMOGLOBIN	14.7	g/dL	13.5 - 17.5	Photometric
RBC COUNT	5.2	10^6/μL	4.3 - 5.7	Electrical Impedance
HEMATOCRIT	43.5	%	38 - 50	Calculation
MCV	84.5	fL	82 - 98	Calculation
МСН	28.5	pg	27 - 32	Calculation
мснс	33.7	g/dL	32 - 37	Calculation
* RDW	13.2	%	11.8 - 15.6	Calculation
* RDW-SD	38.90	fL		Calculation
MPV	8.8	fL	7.6 - 10.8	Calculation
PLATELET COUNT	184	10^3/uL	150 - 450	Electrical Impedance
* NUCLEATED RBC (NRBC)	0.20	/100 WBC		VCS 360 Technology
* ABSOLUTE NRBC COUNT	0.01	10^3/uL		Calculation
TOTAL & DIFFERENTIAL COUNT (DC)				
WBC COUNT	6.3	10^3/μL	4 - 11	Electrical Impedance
NEUTROPHILS	60	%	40 - 75	VCS 360 Technology
LYMPHOCYTES	35	%	20 - 45	VCS 360 Technology
EOSINOPHILS	1	%	0 - 6	VCS 360 Technology
MONOCYTES	4	%	1 - 6	VCS 360 Technology
BASOPHILS	0	%	0 - 1	VCS 360 Technology
ABSOLUTE COUNT				
ABSOLUTE NEUTROPHIL COUNT	3.8	10^3/uL	1.6 - 8.25	Calculation
ABSOLUTE LYMPHOCYTE COUNT	2.2	10^3/uL	0.8 - 4.95	Calculation
ABSOLUTE MONOCYTE COUNT	0.3	10^3/uL	0.04 - 0.66	Calculation
ABSOLUTE EOSINOPHIL COUNT	0.1	10^3/uL	0 - 0.66	Calculation
ABSOLUTE BASOPHIL COUNT	0	10^3/uL	0 - 0.11	Calculation

Sample Type: EDTA Whole Blood

ayena V. Shah

DR. ADLEY MARK FERNANDES

M.D (Pathology)

Pathologist

DR. VYOMA SHAH

M.D (Pathology)

Clinical Pathologist

Printed on:

HALEEM HAKKIM

Laboratory Technician

d on: 16-Jul-2025 11:57 PM

This is an Electronically Authenticated Report.











Mr. MHD SALEEM KHALED

PID NO: 43120

Age: 25 Years Sex: Male DOB: 07-Jul-2000

Reference: Dr. AISHA

Referred Client:

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5070106064

Collected on:

16-Jul-2025 03:25 PM

Registered on:

16-Jul-2025 11:14 PM

Reported on:

16-Jul-2025 11:55 PM

Investigation

Observed Value

< 0.6

Flag <u>Unit</u> **Biological Reference Interval**

* C-REACTIVE PROTEIN (CRP)

(Serum, Particle-enhanced immunoturbidimetric assay)

mg/L

Please note change.

Source: Roche IFU.

INTERPRETATION:

- CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
- C-reactive protein is the classic acute phase protein in inflammatory reactions.
- CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis).
- CRP response may be less pronounced in patients suffering from liver disease.
- CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection."

----- End Of Report ------

DR. ADLEY MARK FERNANDES

This is an Electronically Authenticated Report.

M.D (Pathology)

DR. VYOMA SHAH M.D (Pathology) **Clinical Pathologist**

ayona V. Shah

ACCREDITED

192 - LBPMBe 2 of 2



Printed on: 16-Jul-2025 11:57 PM

M RASHID CHENANGADATH

Laboratory Technologist